Julien de Salaberry is the CEO and founder of Galen Growth Asia (GGA) headquartered in Singapore. This thought leader and digital-health advocate calls himself a “healthcare change catalyst and evangelist who challenges the status quo in healthcare whilst understanding the world in which healthcare providers and organizations function.” With over 15 years of experience in healthcare with leading brands including Eli Lilly, Boston Scientific, Baxter, GSK, and Merck & Co., Julien has a deep understanding of organic and inorganic growth in healthcare in both developed and emerging markets. He has extensive experience all over Europe, the Middle East, and Asia in venture investments and startup advisory environments.

He has created a fund for research and innovation collaboration with cancer as the focus, and now leads GGA, research, analytics, advisory firm (and serious collaboration builder) dedicated to transforming the standard of healthcare in Asia Pacific (AP) through nurturing innovation.

I asked Julien to respond to some questions relevant to GGA’s role to help determine the value of HealthTech and get his perspective on where startups are making a difference. But, first, I felt it key to ask the man passionate about disrupting and improving the HealthTech landscape (and, who clearly isn’t a native to Singapore), why Asia? Insightful responses follow.